Decisions That Made A Difference: Wockhardt Chief On A Life In Business
Executive Summary
Dr Habil Khorakiwala, Wockhardt’s chair and group CEO, recounts his life and business journey, including an acquisition that went wrong, in an interview with Scrip as part of our ongoing executive profile series. Khorakiwala also outlines where he sees Wockhardt in the coming years, with the firm’s R&D thrust in the antibiotics space expected to play a pivotal role.
You may also be interested in...
Wockhardt Refuses To Comment On Formulations Demerger
Wockhardt has stayed quiet on reports that it is planning to spin off its formulations business into a separate operation and then sell a sizeable chunk of it to cut a massive debt load.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet